PDGF and FGF2 Regulate Oligodendrocyte Progenitor Responses to Demyelination

Emma E. Frost,1 Joseph A. Nielsen,2 Tuan Q. Le,1 Regina C. Armstrong1,2

1 Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799
2 Program in Molecular and Cell Biology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799

Received 18 January 2002; accepted 6 August 2002

ABSTRACT: Acute demyelination of adult CNS, resulting from trauma or disease, is initially followed by remyelination. However, chronic lesions with subsequent functional impairment result from eventual failure of the remyelination process, as seen in multiple sclerosis. Studies using animal models of successful remyelination delineate a progression of events facilitating remyelination. A universal feature of this repair process is extensive proliferation of oligodendrocyte progenitor cells (OPs) in response to demyelination. To investigate signals that regulate OP proliferation in response to demyelination we used murine hepatitis virus-A59 (MHV-A59) infection of adult mice to induce focal demyelination throughout the spinal cord followed by spontaneous remyelination. We cultured glial cells directly from demyelinating and remyelinating spinal cords using conditions that maintain the dramatically enhanced OP proliferative response prior to CNS remyelination. We identify PDGF and FGF2 as significant mitogens regulating this proliferative response. Furthermore, we demonstrate endogenous PDGF and FGF2 activity in these glial cultures isolated from demyelinated CNS tissue. These findings correlate well with our previous demonstration of increased in vivo expression of PDGF and FGF2 ligand and corresponding receptors in MHV-A59 lesions. Together these studies support the potential of these pathways to function in vivo as critical factors in regulating remyelination.

INTRODUCTION

Oligodendrocyte myelination of CNS axons facilitates conduction of electrical signals between neurons. In demyelinating diseases, such as multiple sclerosis (MS), myelin damage results in impaired conduction and progresive axonal degeneration. Limited spontaneous remyelination occurs in acute MS lesions, yet recurring myelin damage is not sufficiently repaired (Raine and Wu, 1993; Prineas et al., 1993). The cellular and molecular mechanisms of remyelination are not clear, however, a key feature is the generation of remyelinating cells from local precursor cells. Several studies have identified immature oligodendrocyte lineage cells (OLCs) in the normal adult human CNS (Wolswijk and Noble, 1989; Armstrong et al., 1992; Scolding et al., 1995; Roy et al., 1999), and the density of these immature OLCs is increased in acute MS lesions (Chang et al., 2000; Maeda et al., 2001). These precursor cells may serve as targets for developing therapeutic strategies to improve OLC regeneration and the extent of remyelination in human demyelinating diseases.
Regulatory mechanisms involved in remyelination can be readily analyzed in adult rodent CNS models that achieve successful remyelination in response to acute demyelination. Oligodendrocyte progenitor cells (OPs) persist in the adult rodent CNS (ffrench-Constant and Raff, 1986; Armstrong et al., 1990; Gensert and Goldman, 1997; Horner et al., 2000). In several models of transient demyelination, OP proliferation occurs prior to remyelination (e.g., Carroll et al., 1998; Keirstead et al., 1998; Redwine and Armstrong, 1998). Several developmentally important trophins are expressed in normal adult rodent CNS, and may be more abundant in remyelinating rodent CNS (reviewed in Armstrong, 2000). As candidate molecules regulating OP responses in remyelinating tissue, we focus on PDGF and FGF2, two relatively well-characterized trophins for developing OPs.

We use murine hepatitis virus A-59 (MHV-A59) to induce transient focal demyelination throughout the spinal cord, which is followed by spontaneous remyelination and functional recovery (Jordan et al., 1989; Redwine and Armstrong, 1998). Our previous studies have shown an up-regulation of platelet-derived growth factor receptor-α (PDGFαR) expressing cells associated with MHV-A59 lesions, and corresponding increases in PDGF-A ligand (Redwine and Armstrong, 1998). We have also shown significant increases in FGF2 ligand and receptor expression in these remyelinating lesions (Messersmith et al., 2000). Thus, PDGF and FGF2 ligands and receptors are expressed during remyelination with a temporal, spatial, and cellular distribution consistent with a potential role in generating remyelinating OLCs.

In this study we use glial cultures isolated at specific stages of MHV-A59 disease progression to directly examine the role of PDGF and FGF2 in regulating OLC proliferation and differentiation associated with remyelination. We investigate the activity of PDGF-AA and FGF2, each tested singly and in combination. In addition, we examine the significance of endogenously produced PDGF and FGF2 in the cultures using inhibitors specific to each pathway. Importantly, at two distinct phases of disease progression, demyelination and early remyelination, we compare OLC responses elicited by exogenous and endogenous PDGF and FGF2. We show that adult OP responses are clearly regulated by PDGF and FGF2, especially acting in combination, and that the OP responses differ with disease state.

**MATERIALS AND METHODS**

**MHV-A59 Injection**

As previously described (Redwine and Armstrong, 1998), MHV-A59 virus stock (1000 PFU in 10 μL) was injected intracranially into 28-day-old C57Bl/6 female mice (Charles River, Wilmington, MA) to produce focal areas of transient demyelination throughout the rostrocaudal extent of the spinal cord white matter. Motor impairment was quantified by recording the period of time mice were able to hang upside down supporting their weight by gripping the bars of a metal cage top, with a maximum period set at 60 s (Redwine and Armstrong, 1998). Measurements were taken on days 7, 10, 14, 17, 21, 25, 28, and 32 days postinjection (dpi). The extent of demyelination was classified as “severely” affected if the mice were unable to hang on to the cage top for at least 30 s on 2 or more test days during the first 14 dpi. All animals were handled in accordance with procedures approved by the USUHS Institutional Animal Care and Use Committee.

**Tissue Preparation**

As previously described (Redwine and Armstrong, 1998), mice were perfused with 4% paraformaldehyde and the spinal cords removed. For histological observation, tissue was osmicated, embedded in plastic, cut into 1 μm semithin sections, and stained with toluidine blue. For immunostaining, spinal cord segments were postfixed overnight, cryoprotected with 30% sucrose, embedded in Tissue Tek OCT compound, and stored at −80°C.

**Immunostaining of Tissue Sections**

Fifteen-micrometer cryosections were thaw mounted onto Superfrost slides and immunostained for NG2 and PDGFαR to identify OPs *in situ* (Redwine and Armstrong, 1998; Messersmith et al., 2000). Primary antibodies used were rabbit polyclonal anti-NG2 antibody (1:500; a generous gift from Dr. William Stallcup) and rat monoclonal anti-PDGFαR antibody (1:200; Pharmingen, San Diego, CA). Donkey antirabbit Cy3 conjugate (Jackson Immunoresearch, West Grove, PA) was used to detect NG2 and the PDGFαR was detected with biotinylated donkey antirabbit F(ab’)2 (Jackson Immunoresearch) with FITC-tyramide amplification (New England Nuclear, Boston, MA). Sections were stained with DAPI (Sigma) prior to mounting.

**In Situ Hybridization**

*In situ* hybridization and preparation of digoxigenin-labeled riboprobes were performed as previously published for analysis of MHV-A59 spinal cord sections (Redwine and Armstrong, 1998; Messersmith et al., 2000). The digoxigenin-labeled riboprobe used to detect FGF2 was prepared from a cDNA template complementary to nucleotides 1–475 of mouse FGF2 (gift from Dr. Gail Martin, University of California at San Francisco; Hebert et al., 1990). The cDNA template used for PDGF-A (kindly provided by Dr. Mark Mercola, Harvard Medical School) was complementary to an approximated 0.9 kb mRNA fragment of mouse PDGF-A mRNA (Mercola et al., 1990). The cDNA template for the proteolipid protein (PLP) ribonucleotide probe
(gift from Dr. Lynn Hudson, National Institutes of Health) was complementary to a 980 bp fragment of the mouse PLP mRNA sequence (Hudson et al., 1987). An in vitro transcription kit (Ambion, Austin, TX) was used to incorporate digoxigenin-UTP (Boehringer Mannheim, Indianapolis, IN). The digoxigenin-labeled riboprobes were hybridized to mixed glial cultures prepared from spinal cords of 4 weeks postinjection (wpi) MHV-A59 severely affected mice. Digoxigenin was detected with an alkaline phosphatase-conjugated sheep antidigoxigenin antibody (Boehringer Mannheim), followed by reaction with NBT/BCIP substrate (DAKO, Carpinteria, CA).

**Neonatal Brain Oligodendrocyte Precursor Cell Isolation**

Neonatal OPs (nOPs) were prepared from postnatal day 2 rat brains, by a method detailed in Armstrong (1998). Approximately 10–14 days after plating, the nOPs and microglia were dislodged by shaking the flasks, followed by plating on noncoated tissue culture plastic to allow the differential adhesion of microglial cells. The nOP cell suspension was collected, concentrated, and resuspended in Sato’s defined medium with high insulin (Bottenstein and Sato, 1979), which is Dulbecco’s modified Eagle’s medium (DME; Life Technologies, Rockville, MD) supplemented with the following reagents (from Sigma, St. Louis, MO unless otherwise stated): 25 µg/mL gentamicin (Life Technologies), 5 µg/mL bovine insulin, 50 µg/mL human transferrin, 100 µg/mL bovine serum albumin (BSA) fraction V, 66 ng/mL progesterone, 16 µg/mL putrescine, 5 ng/mL sodium selenite, 400 ng/mL thyroxine (T4), and 400 ng/mL tri-iodothyronine (T3) (Biofluids Inc., Rockville, MD).

**Inhibitors of PDGF and FGF2**

Rat brain nOP cells proliferate extensively and reproducibly in response to either PDGF-AA or FGF2 (McKinnon et al., 1990; Baron et al., 2000). Therefore, nOPs were used to characterize the specificity of inhibitors of each growth factor pathway.

OPs express only one of the PDGF receptor isoforms, the alpha receptor (PDGFRα) (Hart et al., 1989; Pringle et al., 1992). The PDGFRα is a protein tyrosine kinase receptor with numerous sites of phosphorylation that interact with several different signal transduction molecules (Heldin and Westermark, 1999). Therefore, to block activity of the PDGF pathway, we selected a specific inhibitor of the kinase activity of the PDGFRα. The AG1295 compound (Calbiochem, La Jolla, CA) is 6,7-dimethyl-2-phenylquinoxaline, a tyrosphosphatase selective inhibitor of phosphorylation by the PDGFRα receptor tyrosine kinase. AG1295 has previously been shown to have no effect on autophosphorylation of the epidermal growth factor receptor even at concentrations up to 100 µM (Kovalenko et al., 1994). Kovalenko et al. (1994) further showed that the IC50 for AG1295 inhibition of DNA synthesis in Swiss 3T3 cells was 2.5 µM. Other studies have used 10 µM AG1295 to specifically inhibit PDGFRα receptor activation (Banai et al., 1998; Iwamoto et al., 2000). A dose response curve (1.0, 2.5, 10, and 25 µM) of AG1295 was used to test the inhibition of proliferation of nOPs in response to 10 ng/mL PDGF-AA. Based upon the results with nOPs a single concentration of 10 µM AG1295 was used for the adult OLC proliferation studies.

In contrast to the single receptor types of the PDGF pathway, OLCs express at least three different FGF receptor types (Bansal et al., 1996; Messersmith et al., 2000). In addition, the FGF receptors are activated by multiple ligands of the FGF family (Ornitz et al., 1996; Ornitz and Itoh, 2001). Therefore, to specifically investigate the role of FGF2 ligand in the regulation of OLC proliferation, we used an anti-FGF2 neutralizing antibody (FGF2nAb) that has been used to block activity of FGF2 in vivo (Nilsson et al., 2001). The FGF2nAb (AF-233-NA; R&D Systems, Minneapolis, MN) was used at a concentration of 1 µg/mL, which is the manufacturer recommended ND50, and is 10X the concentration required to block maximal proliferation of NIH3T3 cells in response to rhFGF2.

**Proliferation Assay**

The purified nOPs were gently triturated to produce a single cell suspension. Cells were then plated at 10,000 cells per 12 mm PDL-coated glass coverslip in Sato’s defined medium supplemented with 0.5% fetal bovine serum (FBS) (Life Technologies), 10 ng/mL PDGF-AA (R&D Systems), and 10 ng/mL FGF2 (R&D Systems) overnight. The following day the medium was replaced with serum/growth factor-free Sato’s medium for 6 h. The medium was then replaced with serum-free Sato’s medium containing 10 ng/mL PDGF-AA or FGF2 with or without inhibitors, and 10 µM BrdU (Boehringer Mannheim) for 19 h.

To prepare cells for immunodetection of incorporated BrdU, the cells were washed with cold HEPES buffered Minimal Essential Medium (Life Technologies), fixed in methanol at −20°C for 10 min, then treated for 1 min with 0.2% paraformaldehyde, washed, treated with 0.07 M NaOH for 7 min, washed, then treated with 2% paraformaldehyde for 3 min. Monoclonal anti-BrdU antibody (0.25 µg/mL in PBS; Beckton Dickinson, San Jose, CA) was added to the cells for 30–60 min at room temperature (RT) and detected with donkey antimouse IgG (H+L) F(ab’)2 FITC conjugate (Jackson Immunoresearch). Cells were stained with the nuclear stain DAPI (Sigma) prior to mounting. Cell proliferation was assessed as the percentage of DAPI− nOPs that were also BrdU+.

At least 100 cells per coverslip were counted with three to four coverslips per experiment and three experiments per inhibitor.

**Cell Viability Assay**

Purified nOPs were prepared as for the proliferation assay. Propidium iodide (PI) (20 µg/mL; Sigma), which is excluded from live cells, was added to each coverslip for 10 min. Cells were then fixed with 4% paraformaldehyde for 10 min at RT and stained with DAPI (see above). Cell viability was assessed as the percentage of DAPI+ PI− nOPs.
per coverslip. At least 100 cells per coverslip were counted, with three to four coverslips per experiment and three experiments per growth factor pathway inhibitor.

**Mixed Glial Cell Preparation from Spinal Cord**

Only mice meeting the criteria of severely affected were used for tissue culture. Mice were sacrificed at either of two stages of the disease progression: at 14–17 dpi (“2 wpi”), or at 28–32 dpi (“4 wpi”). Spinal cords were removed from six mice for each mixed glial cell preparation. Whole spinal cords were used in this study because of the uncertainties of the anatomical locations of various potential pools of precursor cells that may contribute to remyelination, and because prolonged microdissection time to isolate the multiple cursor cells that may contribute to remyelination, and be the anatomical locations of various potential pools of precursor cells that may contribute to remyelination, and be

**Immunocytochemistry**

Cultured OLCs from MHV-A59 were identified using three-color immunofluorescence with differentiation stage-specific markers. Anti-NG2 antibody recognizes a chondroitin sulphate proteoglycan that is expressed by OPs (Nishiyama et al., 1996a,b). O1 monoclonal antibody recognizes a cell surface galactocerebroside that is a marker of mature oligodendrocytes (Bansal and Pfeiffer, 1992). BrdU was added to the cultures for 19 h, with O1 antibody (1:10 supernatant from hybridoma cultures containing 10% FBS in DME) being added for the final hour at 37°C. The cells were then fixed, permeabilized, and incubated with anti-BrdU as detailed above. Donkey antimouse IgG (H+L) F(ab’2) FITC conjugate was used to detect the BrdU, and goat antimouse IgM TRITC conjugate (Jackson Immunoresearch) was used to detect the O1, for 30 min at RT. Cells were then incubated overnight at 4°C with rabbit polyclonal anti-NG2 antibody (1:250–500 dilutions; generous gifts from Dr. Joel Levine and Dr. William Stallcup). NG2 was detected with AMCA conjugated, donkey antirabbit secondary antibody (Jackson Immunoresearch) at RT for 30 min. Cultures were also analyzed for O4 and GFAP immunoreactivity to identify a broad range of OLC stages and the astrocytic cell population. In these experiments, cultures were treated as detailed above, substituting O4 antibody (1:10 dilution of supernatant from hybridoma cultures and containing 10% FBS in DME) for the O1 antibody, and GFAP (0.41 μg/mL; Dako, Carpinteria, CA) for the NG2 antibody. Cells were then counted using a Zeiss Photoscope III. Thirty different fields of view using a 25X objective with a 1.25-optivar were counted per dish, which covered approximately 12.5% of the total measurable area of the dish. Prior to analyzing the dishes, we verified that 30 fields of view were a representative sample and complied with assumptions necessary for this analysis (i.e., normality of distributions and homogeneity of variances).

**Clonal Analysis**

Mixed glial spinal cord cultures were prepared as detailed above. A combination of PDGF-AA and FGF2, or a combination of the inhibitors AG1295 and FGF2nAb, was added to the dishes at day 2. After a further 24 h, the BAG replication-deficient retrovirus [80 plaque forming units (PFU); Price et al., 1987; Levison et al., 1999; generously provided by Dr. Steve Levison, Penn State University, Hershey, PA] was added to the cultures, which were returned to the incubator for a further 48 h. O1 or O4 monoclonal antibody (as detailed above) was added to the medium for the final 60 min. The dishes were then fixed in 2% paraformaldehyde and the O1 or O4 monoclonal antibody was detected as detailed above. The cultures were then incubated for 24 h at 4°C with anti-NG2 (as above) and β-galactosidase (β-gal) using the 40-1A monoclonal antibody (1:2 dilution of supernatant from hybridoma cultures containing 15% FBS in DME). The hybridoma cells were obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the NICHD and maintained by the University of Iowa, Department of Biological Sciences (Iowa City, IA, 52242). Monoclonal 40-1A was detected with donkey antimouse IgG FITC (Jackson Immunoresearch). All labeled clones were counted within each dish.

**Imaging**

All images were collected using a Spot II Camera (Diagnostic Instruments, Inc.) attached to an Olympus IX70 epifluorescence microscope, with associated software and Photoshop 5.0.
RESULTS

The role of PDGF and FGF2 in the regulation of OLC proliferation and differentiation during demyelination and remyelination was investigated using glial cell cultures isolated from spinal cords of MHV-A59 infected adult mice. To ensure that reproducibly affected mice were used in each culture preparation, motor impairment was monitored by measuring the length of time the MHV-A59 injected mice were able to hang upside down from the wires of a cage top and support their weight (Fig. 1). Mice unable to hang for a minimum of 30 s or less, for at least two out of the first three test dates (days 7, 10, 14), were classified as severely affected (Redwine and Armstrong, 1998).

Previous studies have shown demyelinated lesions beginning at 1 wpi with more extensive areas of myelin degeneration by 2 wpi (Jordan et al., 1989; Armstrong et al., 1990). In subsequent weeks, myelin debris is cleared and remyelination is initiated (Jordan et al., 1989; Redwine and Armstrong, 1998).

In the current study, the overall area of demyelination throughout the spinal cord was assessed in a representative severely affected mouse by measuring the area of lesion in toluidine blue stained sections [Fig. 2(A); n = 152 sections throughout the spinal cord]. Characteristic areas of focal demyelination were observed in each funiculus. The proportion of white matter area with myelin loss was 18.3 ± 3.6%, 12.9 ± 2.2%, and 24.0 ± 4.2% for cervical, thoracic, and lumbar levels, respectively. In addition to myelin loss, lesions typically exhibited vacuolation and in-
creased cell density [Fig. 2(A)]. Lesion areas showed accumulation of OPs, which were identified by immunostaining for NG2 and PDGFαR [Fig. 2(B,C)].

To analyze OP responses, cultures were prepared from spinal cords of mice sacrificed at two distinct phases of disease progression. The time of sacrifice was restricted to within a 5 day window of each phase to minimize variation within disease progression. Within the demyelination phase, 14–17 days after MHV-A59 injection was used as the earliest point at which the mice could be classified as “severe” to be used for preparations of cultures. These cultures are referred to as 2 wpi. This period corresponds with severe loss of motor function and the viral infection of the white matter (Jordan et al., 1989). Cultures were also prepared from tissue 28–32 days postinjection (referred to as 4 wpi). This period corresponds with recovery of motor function (Fig. 1) and viral clearance (Jordan et al., 1989; Redwine and Armstrong, 1998). For each cell preparation, spinal cords from six severely affected mice were combined in order to minimize the variability between mice.

Identification of Glial Cell Types in Cultures from Spinal Cords of MHV-A59 Infected Mice

The cell types in the cultures were characterized using three-color immunofluorescence. Cell type-specific antibodies facilitated the identification of specific stages of differentiation of the OLCs within the cultures (see Materials and Methods). In addition, BrdU incorporation was used to identify proliferating cells with each antigenic phenotype. OPs were identified as NG2⁺, O1⁻. Transitional oligodendrocytes were identified as NG2⁺, O1⁺. Differentiated oligodendrocytes were identified as NG2⁻, O1⁺ (Fig. 3).

An extracellular matrix culture substrate was used to promote the adhesion of OLCs of all differentiation stages as well as astrocytes and microglia, as previously shown (Armstrong et al., 1990). Experiments using glial fibrillary acidic protein (GFAP) as a marker for astrocytes confirmed that these cultures contained astrocytes, upon which the OLCs were often observed (not shown). Cells with astrocytic morphology and those with microglial morphology were also prevalent within the cultures (Fig. 4).

In Situ Hybridization Analysis of Growth Factor mRNA Expression in Cultures from Spinal Cords of MHV-A59 Infected Mice

Previous studies have shown that activated astrocytes and microglial cells synthesize and secrete both PDGF and FGF2 within demyelinated lesions (Redwine and Armstrong, 1998; Messersmith et al., 2000; Liu et al., 1998). Therefore, de novo synthesis of
PDGF-A and FGF2 by cells within the mixed glial cultures was demonstrated using in situ hybridization. Mixed glial cultures were prepared as described above. In cultures isolated at 4 wpi, both astrocytes and microglial cells exhibited PDGF-A and FGF2 mRNA signal [Fig. 4(A,B)]. Signal intensity in astrocytes appeared to be greater for FGF2 than for PDGF-A, which is consistent with results seen in this model in vivo (Redwine and Armstrong, 1998; Messersmith et al., 2000). Cultures were also analyzed for PLP mRNA [Fig. 4(C,D)], a marker of mature oligodendrocytes, and FGF2 sense mRNA [Fig. 4(E,F)], to demonstrate specificity of the in situ hybridization detection.

Characterization of Growth Factor Inhibitors

To investigate the role of endogenously produced PDGF and FGF2 in the regulation of proliferation in these cultures we used reagents that inhibited each growth factor pathway. The tyrphostin compound AG1295 was used to inhibit PDGFαR tyrosine kinase phosphorylation. The activity of FGF2 was inhibited with a neutralizing antibody (FGF2nAb).

The specificity of each inhibitor was demonstrated using BrdU incorporation in neonatal rat cortical OP cultures (nOP), in which PDGF and FGF2 have been characterized as potent mitogens (McKinnon et al., 1990; Baron et al., 2000). AG1295 is a specific inhibitor of PDGF receptor activated DNA synthesis, with an IC_{50} of 2.5 μM in Swiss 3T3 cells (Kovalenko et al., 1994) that has previously been shown to inhibit PDGF induced proliferation of several different cell types (for example Banai et al., 1998; Iwamoto et al., 2000). In this study a dose response analysis of AG1295 showed that 2.5 μM AG1295 only inhibited PDGF induced proliferation by 9.1%, whereas 10 μM AG1295 inhibited PDGF induced proliferation by 35.8%, back to levels seen in cultures without PDGF (Fig. 5). Previous studies have demonstrated that at 10 μM, AG1295 inhibited the phosphorylation of PDGF
Within glial cultures derived from demyelinated spinal cord at 2 wpi and then grown for 2 days in vitro (div) in DFM, 42% of the OLCs had incorporated BrdU. The majority of these OLCs were NG2+ OPs [Fig. 6(A)]. After a further 3 days in defined medium alone (control), the total percentage of proliferating cells did not change significantly. The addition of exogenous PDGF-AA and FGF2 for these 3 div also did not significantly change the total proportion of proliferating OLCs, even when added in combination [Fig. 6(A)]. One possible explanation for this result is that the OLCs are responding maximally to endogenous growth factors synthesized by cells within the cultures. Indeed, inhibition of endogenously produced PDGF and FGF2 activity using AG1295 and FGF2nAb, either individually or in combination, significantly reduced both the total percentage of proliferating OLCs and the proportion of NG2+ OPs that had incorporated BrdU (Fig. 6).

**Figure 5** Characterization of growth factor specific inhibitors. The specificity of the PDGFrR inhibitor AG1295 and the anti-FGF2 neutralizing antibody (FGF2nAb) was assessed in neonatal rat brain OPs (nOP) using BrdU incorporation as a marker of proliferation. Black bars denote PDGF-AA treated nOPs and gray bars denote FGF2 (FGF2) treated nOPs. AG1295 (10 μM) maximally inhibited PDGF-AA (10 ng/mL) stimulated proliferation of nOPs, with no marked effect on FGF2 induced proliferation. The FGF2nAb at 1 μg/mL significantly inhibited proliferation induced by FGF2 (10 ng/mL) with no marked effect on PDGF-AA induced proliferation. Each value (±S.E.M.) represents four experiments with three to four replicates and at least 100 cells were counted per coverslip (**p < .005 compared to growth factor condition without inhibitor). Statistical analysis was paired two-tailed t test analysis.

**Endogenous PDGF and FGF2 Prevent OLC Differentiation in Cultures of Demyelinated Spinal Cord (2 wpi)**

The OLC population within cultures derived from demyelinated spinal cord (at 2 wpi) consisted primarily of NG2+ OPs [Fig. 7(A), black bars] after 2 div in DFM. After a further 3 div, in defined medium alone (control), there was no change in the proportion of NG2+ OPs [Fig. 7(B)]. The addition of exogenous growth factors did not significantly alter the antigenic phenotype of the OLCs. In contrast, the inhibitors AG1295 and FGF2nAb, both individually and in combination, significantly reduced the proportion of NG2+ OPs among the OLC populations in these cultures (Fig. 7). Consistent with the proliferation analysis (above), these findings indicate that endogenous PDGF and FGF2 signaling prevents OP differentiation during the demyelination stage of the disease progression.

**OP Proliferation in Cultures Derived during Remyelination (4 wpi)**

Within cultures derived from remyelinating spinal cord (at 4 wpi) and then grown for 2 div in DFM, 23% of the OLCs incorporated BrdU [Fig. 8(A)]. This proportion of proliferating OLCs was less than that seen at 2 wpi [Fig. 6(A)] (p < .005). Approximately half of the BrdU labeled OLCs were NG2+ OPs [Fig. 8(A), black bars]. After a further 3 days in defined medium alone (control), the percentage of NG2+ OPs that had incorporated BrdU was significantly reduced by approximately 60%. The addition of exogenous PDGF-AA with FGF2 significantly increased NG2+ OP proliferation [Fig. 8(B)]. The growth factor inhibitors AG1295 and FGF2nAb did not reduce the total
percentage of proliferating OLCs when used individually [Fig. 8(A)]. In combination, however, the inhibitors did significantly reduce the total percentage of OLCs incorporating BrdU [Fig. 8(A)] and the proportion of NG2+ OPs that were BrdU+ [Fig. 8(B)]. Thus, at 4 wpi, endogenous PDGF and FGF2 still contribute to OP proliferation. However, the significant response to exogenous PDGF-AA and FGF2 during remyelination also indicates that endogenous PDGF and FGF2 are no longer acting at saturation levels, and the appropriate growth factor receptors are still available to respond at 4 wpi.

OP Differentiation in Cultures Derived during Remyelination (4 wpi)

The OLC population within the cultures from 4 wpi tissue consisted of predominantly NG2+ OPs [Fig. 9(A)] after 2 div in DFM, similar to that seen in 2 wpi cultures [Fig. 7(A)]. However, in contrast to cultures from 2 wpi, after a further 3 div in defined medium alone, there were significantly fewer NG2+ OPs, with the majority of cells being in later stages of the lineage [Fig. 9(A)] (p = .0027 vs. control). This pattern indicates that OLCs derived from 4 wpi tissue exhibit an increased tendency to differentiate. Thus, OLC differentiation within this culture system correlates with OLC transitions expected for the onset of remyelination at this stage of the disease progression in vivo.

Analysis of OLC differentiation in the cultures from tissue at 4 wpi, with either inhibition or addition of PDGF and FGF2, also indicated differences relative to cultures derived from 2 wpi tissue. In cultures from 4 wpi tissue, AG1295 and FGF2nAb had no effect on OLC differentiation when used either individually or in combination [Fig. 9(A)]. This further supports the suggestion that the OLC response to endogenous PDGF and FGF2 signaling is reduced at 4 wpi relative to 2 wpi. Moreover, addition of PDGF-AA or FGF2, either individually or in combination, significantly increased the proportion of NG2+ OPs compared to defined medium alone (Fig. 9), which is again consistent with maintained expression of growth factor receptors at 4 wpi. This increase may be due to proliferation (see above) that generates more NG2+ OPs. Alternatively, the exogenous PDGF-AA

Figure 6  Endogenous PDGF and FGF2 enhance proliferation of oligodendrocyte lineage cells in mixed glial cultures of demyelinated spinal cords. In cultures prepared from 2-week postinfection (2 wpi) tissue, OLC proliferation was assessed as the percentage of total OLCs (labeled with NG2 and/or O1 stage-specific immunomarkers) that incorporated BrdU during a terminal 19 h pulse. Bars represent NG2+O1− cells, gray bars represent NG2+O1− cells, and white bars represent NG2−O1+ cells. (A) OLC proliferation is not altered by the addition of exogenous PDGF AA and/or FGF2. In contrast, inhibition of either or both endogenous growth factors results in significant inhibition of proliferation. (B) NG2+O1− cell proliferation is not affected by exogenous PDGF-AA or FGF2, however, it is significantly reduced by the inhibition of endogenous PDGF and FGF2. For each value (±S.E.M.) n = 4–6 dishes per treatment across three to four different glial preparations. (p vs. control *p < .05, **p < .01). Statistical analysis was one-way analysis of variance, followed by paired two-tailed t test analysis.
and FGF2 may be maintaining the NG2⁺ OP population by blocking maturation to the O1⁺ stage.

**Clonal Analysis Distinguishes between the Mitogenic and Differentiation Effects of PDGF and FGF2**

To more specifically delineate the roles of PDGF and FGF2 in the regulation of OLC proliferation and differentiation during early remyelination, cells isolated from spinal cords at 4 wpi were infected with the BAG replication-deficient retrovirus. Cells infected with the BAG retrovirus expressed β-gal as a heritable marker that allowed identification of clonally derived cells 48 h after infection (Fig. 10). Because the BAG retrovirus is integrated into the chromosome after mitosis (Hajihosseini et al., 1993), the number of β-gal⁺ OLC clones per dish is proportional to the extent of proliferation of the OLC population, whereas the antigenic phenotype indicates the stage of differentiation.

Cultures grown in defined medium alone (control) contained a mean of six OLC clones per dish (Fig. 11), whereas cultures treated with a combination of PDGF-AA and FGF2 contained approximately twice as many OLC clones per dish. Importantly, in both control dishes and in PDGF-AA- and FGF2-containing medium, the antigenic phenotype of β-gal⁺ OLCs was similar (control = 64.5 ± 3.7% NG2⁺ cells; PDGF + FGF2 treatment = 60.1 ± 1.9% NG2⁺ cells). Therefore, exogenous PDGF-AA and FGF2 did not directly alter differentiation of newly generated OPs at 4 wpi. Further, a combination of the PDGF and FGF2 inhibitors significantly reduced the mean number of clones per culture (Fig. 11), but also had no marked effect on the differentiation state within the clones (51.0 ± 11.6% NG2⁺ cells). Taken together, these data indicate that PDGF and FGF2 in combination regulate OLC generation during remyelination by acting directly as mitogens for OPs.

**DISCUSSION**

Several studies using experimentally induced demyelination have shown increases in OP proliferation associated with remyelination (e.g., Redwine and Armstrong, 1998; Mason et al., 2000; McTigue et al., 2001). However, the mechanisms that induce OP proliferation remain unclear. Using an *in vitro* assay system, this study demonstrates that the proliferation of OPs, during experimentally induced demyelination and remyelination of the adult CNS, is significantly influenced by PDGF and FGF2 acting in combination.

The MHV-A59 coronavirus model used in this...
study is well suited for examining the events surrounding spontaneous remyelination following acute demyelination of the adult mouse CNS. During the first weeks after intracranial injection of the virus, throughout the spinal cord focal lesions develop and are characterized by significant oligodendrocyte loss with subsequent myelin destruction (Jordan et al., 1989). This demyelination of the spinal cord results in paresis, paralysis, and grasping difficulty (represented in Fig. 1; Godfraind et al., 1989; Jordan et al., 1989; Redwine and Armstrong, 1998). Remyelination can be identified by light microscopy at 3–4 wpi, with several wraps of myelin visible by electron microscopy at 4 wpi, which coincides with recovery of motor function (Jordan et al., 1989; Redwine and Armstrong, 1998). The number of remyelinated axons and thickness of myelin continues to progress in subsequent weeks (Jordan et al., 1989; Armstrong et al., 1990).

This study and our previous work (Armstrong et al., 1990) used cultures prepared from spinal cords of MHV-A59 infected mice to examine cellular responses to demyelination and remyelination. To ensure inclusion of all potential pools of progenitors (discussed in Reynolds et al., 2001), entire spinal cords from severely affected mice were used to prepare mixed glial cultures for this study. Using this in vitro system we have previously shown that the total number of OLCs isolated from spinal cords at progressive stages of the MHV-A59 induced disease is significantly increased when compared to age matched controls (Armstrong et al., 1990). The present study shows significantly more OLC proliferation occurring during the demyelination stage of the disease, and more specifically identifies NG2/H11001 OPs as the major proliferative phenotype within the OLC population (Fig. 6). During remyelination (4 wpi) we also found that the total number of OLCs (Armstrong et al., 1990), and more specifically the number of NG2/H11001 OPs (current study, data not shown), was significantly increased compared to age matched control animals (Armstrong et al., 1990). The most proliferative NG2 cells were negative for O1 immunostaining (Figs. 6 and 8). Thus, this technique appears to distinguish progenitors from remyelinating spinal cord compared with a report of normal adult progenitors from optic nerve expressing NG2 or A2B5 with O1 (Shi et al., 1998).

The present study further demonstrates that OPs...
show an increased tendency to differentiate in cultures isolated during remyelination (Fig. 9), as would match the transition appropriate for remyelination in vivo. Thus, our in vitro system maintains the progression of OLC proliferation, accumulation, and differentiation that has been documented to occur in experimental models of demyelination and remyelination in vivo (Ludwin, 1979; Godfraind et al., 1989; Mason et al., 2000; McTigue et al., 2001). Therefore, we can take advantage of this in vitro model to facilitate a reductionist approach to the investigation of putative growth factor and cytokine interactions that regulate OLC responses during spontaneous remyelination of the adult CNS.

Based upon previous developmental and in vitro studies we focused on examining the effects of PDGF and FGF2 signaling to determine the mechanisms cultures when used either individually or in combination. For each value (±S.E.M.) n = 3–6 dishes per treatment across at least four different glial preparations. (p vs. control ***p < .005). Statistical analysis was one-way analysis of variance, followed by paired two-tailed t test analysis.
regulating enhanced OP proliferation in response to demyelination. During development PDGF and FGF2, both individually and in combination, are important regulators of nOP proliferation prior to myelination in the developing CNS (Bögler et al., 1990; McKinnon et al., 1990; van Heyningen et al., 2001). In addition, PDGF and FGF2 regulate the proliferation of OP cells isolated from normal adult optic nerve, spinal cord, and corpus callosum (Wolswijk and Noble, 1992; Engel and Wolswijk, 1996; Mason and Goldman, 2002). Studies of ligand and receptor localization in lesions of the MHV-A59 model provide further support for a potential role for PDGF and FGF2 during demyelination in vivo (Redwine and Armstrong, 1998). In addition, increased FGF2 expression was reported in activated astrocytes and microglia in lesions resulting from MHV-A59 infection (Messersmith et al., 2000) and from experimental allergic encephalomyelitis (Liu et al., 1999).

These findings support the prediction that PDGF and FGF2 are involved in the regulation of OLC proliferation in response to demyelination. Surprisingly, our earlier study showed no effects of exogenous PDGF and FGF2 on the proliferation of OLCs in the cultures derived from MHV-A59 lesioned spinal cords (Armstrong et al., 1990). The present study demonstrates a logical explanation for these previous results being disparate with the predicted role of PDGF and FGF2, and provides further insights into the potential activity of PDGF and FGF2 in the progression of demyelination and remyelination. The current work clearly shows: the importance of the combination of PDGF and FGF2, as well as endogenously produced PDGF and FGF2, in the regulation of OLC proliferation; the NG2+ OP stage of OLCs is most responsive to PDGF and FGF2; depending upon the disease stage used for preparation of the cultures, the NG2+ OP sensitivity varies, possibly in response to changes in the level of exogenous versus endogenous PDGF and FGF2. The mitogenic activity of endogenous PDGF and FGF2 appears most important during the demyelination phase when overall OP proliferation is most robust. Further studies of the growth factor expression within the cultures and the receptor downstream signaling pathways are required to fully elucidate the regulatory mechanism of these growth factor pathways.

In studies using neonatal CNS, PDGF and FGF2 both affect the differentiation state of nOPs, as well as acting as mitogens for nOPs (Bögler et al., 1990; McKinnon et al., 1993; Grinspan et al., 1996; Goddard et al., 1999). The present study used clonal analysis to distinguish between these two different potential roles of PDGF and FGF2 during demyelination. Our results (Fig. 11) show that the differentiation of β-gal+ OLC clones is not affected by the addition of exogenous PDGF and FGF2, whereas OP proliferation is increased. This implies that other putative factors are present in the cultures, and potentially in

**Figure 11** Quantification of clonal analysis. Cultures derived from remyelinating spinal cords (4 wpi) were infected with BAG replication-incompetent retrovirus to introduce β-galactosidase as a heritable marker. OLCs were characterized using antigen-specific markers for the different stages of the oligodendrocyte lineage (as shown in Fig. 10). The number of clones identified within each treatment is an indicator of the level of proliferation within that treatment at the time of retroviral infection. A combination of exogenous PDGF-AA and FGF2 (triangles) increases the total number of OLC clones relative to control conditions (circles). Inhibition of the PDGF and FGF2 (squares) reduces the total number of clones/dish. Each treatment was repeated in four dishes within each of two different glial preparations. Statistical analysis was one-way analysis of variance, followed by paired two-tailed t test analysis.
in vivo, which contribute to the regulation of OLC differentiation.

Increased expression of other growth factors and cytokines has been reported in experimental models of demyelination and may influence OLC responses. Glial Growth Factor 2, TNFα, and TGF-β1 may contribute to a hierarchy of growth factor interaction that, along with PDGF and FGF2, may regulate OP proliferation and differentiation to bring about remyelination (Cannella et al., 1998; Shi et al., 1998; Hinks and Franklin, 1999; Arnett et al., 2001). Other growth factors, such as IGF1, may also promote oligodendrocyte survival in demyelinating diseases (Mason et al., 2000). However, more detailed methods of analysis will be required to clarify the role of other trophins in the regulation of OLCs during remyelination. Further studies will be important to assess the in vivo efficacy of a growth-factor-based therapeutic strategy, and to extend this work to the context of human demyelinating diseases such as multiple sclerosis. The present study illustrates how the control of the effects of growth factor treatment for demyelinating disease may require knowledge of the most responsive cell populations, the interactions among combinations of trophins, and how growth factor therapies may need to be modulated throughout a disease course.

We thank: Drs. Steve Levison, Joel Levine, and Bill Stallcup for reagents; Joshua Murtie and Sue Fletcher for technical assistance and helpful comments; Drs. Katharine Blaschuk, Deb McLaughlin, and Beata Gierdalska for helpful comments and discussion; and Adam Vana and Dr. Yong-Xing Zhou for critical reading of the manuscript.

REFERENCES

Armstrong R, Friedrich Jr VL, Holmes KV, Dubois-Dalcq M. 1990. In vitro analysis of the oligodendrocyte lineage in mice during demyelination and remyelination. J Cell Biol 111:1183–1195.

Armstrong RC. 1998. Isolation and characterization of immature oligodendrocyte lineage cells. Methods 16:282–292.

Armstrong RC. 2000. Potential Roles of Trophic Factors in CNS Development and Recovery from Demyelinating Disease. In: Mocchetti I, editor. Neurobiology of the Trophins. Johnson City, TN: FP Graham Publishing Co. p 333–353.

Armstrong RC, Dorn HH, Kufta CV, Friedman E, Dubois-Dalcq ME. 1992. Pre-oligodendrocytes from adult human CNS. J Neurosci 12:1538–1547.

Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. 2001. TNFα promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4:1116–1122.

Banai S, Wolf Y, Golomb G, Pearle A, Waltenberger J, Fishbein I, Schneider A, Gazit A, Perez L, Huber R, Lazarovichi G, Rabinovich L, Levitzki A, Gertz SD. 1998. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 97:1960–1969.

Bansal R, Kumar M, Murray K, Morrison RS, Pfeiffer SE. 1996. Regulation of FGF receptors in the oligodendrocyte lineage. Mol Cell Neurosci 7:263–275.

Bansal R, Pfeiffer SE. 1992. Novel stage in the oligodendrocyte lineage defined by reactivity of progenitors with R-mAb prior to O1 anti-galactocerebroside. J Neurosci Res 32:309–316.

Baron W, Metz B, Bansal R, Banokstra D, de Vries H. 2000. PDGF and FGF-2 signaling in oligodendrocyte progenitor cells: regulation of proliferation and differentiation by multiple intracellular signaling pathways. Mol Cell Neurosci 15:314–329.

Bögl O, Wren D, Barnett SC, Land H, Noble M. 1990. Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc Natl Acad Sci USA 87:6368–6372.

Bottenstein JE, Sato GH. 1979. Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc Natl Acad Sci USA 76:514–517.

Cannella B, Hoban CJ, Gao YL, Garcia-Arenas R, Lawson D, Marchioni M, Gwyde M, Raine CS. 1998. The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. Proc Natl Acad Sci USA 95:10100–10105.

Carroll WM, Jennings AR, Ironside LJ. 1998. Identification of the adult resting progenitor cell by autoradiographic tracking of oligodendrocyte precursors in experimental CNS demyelination. Brain 121:293–302.

Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. 2000. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci 20:6404–6412.

Engel U, Wolswijk G. 1996. Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells derived from adult rat spinal cord: in vitro characteristics and response to PDGF, bFGF and NT-3. Glia 16:16–26.

French-Constant C, Raff MC. 1986. The oligodendrocyte-type-2 astrocyte cell lineage is specialized for myelination. Nature 323:335–338.

Gensert JM, Goldman JE. 1997. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron 19:197–203.

Goddard D, Berry M, Butt AM. 1999. In vivo actions of fibroblast growth factor-2 and insulin-like growth factor-I on oligodendrocyte development and myelination in the central nervous system. J Neurosci Res 57:74–85.

Godfraind C, Friedrich VL, Holmes KV, Dubois-Dalcq M. 1989. In vivo analysis of glial cell phenotypes during a viral demyelinating disease in mice. J Cell Biol 109:2405–2416.

Grinspan JB, Reeves MF, Coulaloglou MJ, Nathanson D, Pleasure D. 1996. Re-entry into the cell cycle is required
for bFGF-induced oligodendroglial dedifferentiation and survival. J Neurosci Res 46:456–464.

Hajihosseini M, Iavachev L, Price J. 1993. Evidence that retroviruses integrate into post-replication host DNA. Embo J 12:4969–4974.

Hart IK, Richardson WD, Heldin CH, Westermark B, Raff MC. 1989. PDGF receptors on cells of the oligodendrocyte-type-2 astrocyte (O-2A) cell lineage. Development 105:595–603.

Hebert JM, Basilio C, Goldfarb M, Haub O, Martin GR. 1990. Isolation of cDNAs encoding four mouse FGF family members and characterization of their expression patterns during embryogenesis. Dev Biol 138:454–463.

Heldin CH, Westermark B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–1316.

Hinks GL, Franklin RJ. 1999. Distinctive patterns of PDGF-A, FGF-2, IGF-I, and TGF-betal gene expression during remyelination of experimentally-induced spinal cord demyelination. Mol Cell Neurosci 14:153–168.

Horner PJ, Power AE, Kempermann G, Kuhn HG, Palmer TD, Winkler J, Thal LJ, Gage FH. 2000. Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J Neurosci 20:2218–2228.

Hudson LD, Berndt JA, Puckett C, Kozak CA, Lazzarini RA. 1987. Aberrant splicing of proteolipid protein mRNA in the dysmyelinating jimpy mutant mouse. Proc Natl Acad Sci USA 84:1454–1458.

Iwamoto H, Nakamuta M, Tada S, Sugimoto R, Enjoji M, Nawata H. 2000. Platelet-derived growth factor receptor tyrosine kinase inhibitor AG1295 attenuates rat hepatic stellate cell growth. J Lab Clin Med 135:406–412.

Jordan CA, Friedrich Jr VL, Godfraind C, Cardellechio CB, Holmes KV, Dubois-Dalcq M. 1989. Expression of viral and myelin transcripts in a murine CNS demyelinating disease caused by a coronavirus. Glia 2:318–329.

Keirstead HS, Levine JM, Blakemore WF. 1998. Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord. Glia 22:161–170.

Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH, Wallenberger J, Bohmer FD, Levitzki A. 1994. Selective platelet-derived growth factor receptor kinase blockers reverse s-s-transformation. Cancer Res 54:6106–6114.

Leison SW, Young GM, Goldman JE. 1999. Cycling cells in the adult rat neocortex preferentially generate oligodendroglia. J Neurosci Res 57:435–446.

Liu HN, Larocca JN, Almazan G. 1999. Molecular pathways mediating activation by kainate of mitogen-activated protein kinase in oligodendrocyte progenitors. Brain Res Mol Brain Res 66:50–61.

Liu X, Mashour GA, Webster HF, Kurtz A. 1998. Basic FGF and FGF receptor 1 are expressed in microglia during experimental autoimmune encephalomyelitis: temporally distinct expression of midkine and pleiotrophin. Glia 24:390–397.

Ludwin SK. 1979. An autoradiographic study of cellular proliferation in remyelination of the central nervous system. Am J Pathol 95:683–696.

Maeda Y, Solanky M, Menonna J, Chapin J, Li W, Dowling P. 2001. Platelet-derived growth factor-alpha receptor-positive oligodendroglia are frequent in multiple sclerosis lesions. Ann Neurol 49:776–785.

Mason JL, Goldman JE. 2002. A2B5(+) and O4(+) Cycling Progenitors in the Adult Forebrain White Matter Respond Differentially to PDGF-AA, FGF-2, and IGF-1. Mol Cell Neurosci 20:30–42.

Mason JL, Jones JI, Taniike M, Morell P, Suzuki K, Matsushima GK. 2000. Mature oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation and differentiation during demyelination/remyelination. J Neurosci Res 61:251–262.

McKinnon RD, Matsui T, Dubois-Dalcq M, Aaronson SA. 1990. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 5:603–614.

McKinnon RD, Piras G, Ida Jr JA, Dubois-Dalcq M. 1993. A role for TGF-beta in oligodendrocyte differentiation. J Cell Biol 121:1397–1407.

McTighe DM, Wei P, Stokes BT. 2001. Proliferation of NG2-positive cells and altered oligodendrocyte numbers in the contused rat spinal cord. J Neurosci 21:3392–3400.

Mercola M, Wang CY, Kelly J, Brownlee C, Jackson-Grusby L, Stiles C, Bowen-Pope D. 1990. Selective expression of PDGF A and its receptor during early mouse embryogenesis. Dev Biol 138:114–122.

Messenbrink DJ, Murrie JC, Tho QT, Frost EE, Armstrong RC. 2000. Fibroblast growth factor 2 (FGF2) and FGF receptor expression in an experimental demyelinating disease with extensive remyelination. J Neurosci Res 62:241–256.

Nilsson E, Parrott JA, Skinner MK. 2001. Basic fibroblast growth factor induces primordial follicle development and initiates folliculogenesis. Mol Cell Endocrinol 175:123–130.

Nishiyama A, Lin XH, Giese N, Heldin CH, Stallcup WB. 1996a. Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. J Neurosci Res 43:299–314.

Nishiyama A, Lin XH, Giese N, Heldin CH, Stallcup WB. 1996b. Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. J Neurosci Res 43:315–330.

Orntz DM, Itoh N. 2001. Fibroblast growth factors. Genome Biol 2:reviews3005.1–3005.12.

Orntz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulter F, Gao G, Goldfarb M. 1996. Receptor specificity of the fibroblast growth factor family. J Biol Chem 271:15292–15297.

Price J, Turner D, Cepko C. 1987. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA 84:156–160.

Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. 1993. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 33:137–151.

Pringle NP, Mudhar HS, Collarini EJ, Richardson WD. 1992. PDGF receptors in the rat CNS: during late neurogenesis, PDGF alpha-receptor expression appears to be restricted to glial cells of the oligodendrocyte lineage. Development 115:535–551.
Raine CS, Wu E. 1993. Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol 52:199–204.
Redwine JM, Armstrong RC. 1998. In vivo proliferation of oligodendrocyte progenitors expressing PDGFalphaR during early remyelination. J Neurobiol 37:413–428.
Reynolds R, Cenci di Bello I, Dawson M, Levine J. 2001. The response of adult oligodendrocyte progenitors to demyelination in EAE. Prog Brain Res 132:165–174.
Roy NS, Wang S, Harrison-Restelli C, Benraiss A, Fraser RA, Gravel M, Braun PE, Goldman SA. 1999. Identification, isolation, and promoter-defined separation of mitotic oligodendrocyte progenitor cells from the adult human subcortical white matter. J Neurosci 19:9986–9995.
Scolding NJ, Rayner PJ, Sussman J, Shaw C, Compston DA. 1995. A proliferative adult human oligodendrocyte progenitor. NeuroReport 6:441–445.
Shi J, Marinovich A, Barres BA. 1998. Purification and characterization of adult oligodendrocyte precursor cells from the rat optic nerve. J Neurosci 18:4627–4636.
van Heyningen P, Calver AR, Richardson WD. 2001. Control of progenitor cell number by mitogen supply and demand. Curr Biol 11:232–241.
Wolswijk G, Noble M. 1989. Identification of an adult-specific glial progenitor cell. Development 105:387–400.
Wolswijk G, Noble M. 1992. Cooperation between PDGF and FGF converts slowly dividing O-2A adult progenitor cells to rapidly dividing cells with characteristics of O-2A perinatal progenitor cells. J Cell Biol 118:889–900.